NCT04944069

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Almonertinib Combined With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis: A Prospective, Open-label, Multi-center, Single-arm Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 69 (estimated)
• Sponsor: Second Affiliated Hospital of Nanchang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A prospective, open-label, multi-center, single-arm study of Almonertinib combined With Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis.

Detailed description

This is a prospective, open-label, multi-center, single-arm study to evaluate the efficacy and safety of Almonertinib combined with Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis. ALL patients were treated with Almonertinib 110mg oral daily and Bevacizumab 15mg/kg intravenous every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent.

Conditions

• NSCLC
• Leptomeningeal Metastasis
• EGFR Activating Mutation

Interventions

Type	Name	Description
DRUG	Almonertinib	110 mg oral once daily
DRUG	Bevacizumab	15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)

Timeline

• Start date: 2021-07-01
• Primary completion: 2024-03-01
• Completion: 2025-03-01
• First posted: 2021-06-29
• Last updated: 2021-06-29

Locations

1 site across 1 country: China